$106.6 M

TSHA Mkt cap, 20-May-2022
Taysha Gene Therapies Net income (FY, 2020)-60 M
Taysha Gene Therapies EBIT (FY, 2020)-43 M
Taysha Gene Therapies Cash, 31-Dec-2020251.3 M
Get notified regarding key financial metrics and revenue changes at Taysha Gene TherapiesLearn more
Banner background

Taysha Gene Therapies Income Statement

Annual

USDFY, 2019FY, 2020

R&D expense

987.0k31.9m

General and administrative expense

128.0k11.1m

Operating expense total

1.1m43.0m

EBIT

(1.1m)(43.0m)

Interest expense

28.0k

Interest income

49.0k

Net Income

(1.1m)(60.0m)

EPS

(0.1)(3.4)

Quarterly

USDQ3, 2020

R&D expense

11.1m

General and administrative expense

4.0m

Operating expense total

15.0m

EBIT

(15.0m)

Interest expense

1.0k

Net Income

(15.0m)

EPS

(1.3)

Taysha Gene Therapies Balance Sheet

Annual

USDFY, 2019FY, 2020

Cash

251.3m

Prepaid Expenses

6.6m

Current Assets

15.0k257.9m

PP&E

287.0k

Total Assets

15.0k258.9m

Accounts Payable

2.0m

Current Liabilities

150.0k7.1m

Total Liabilities

150.0k7.6m

Additional Paid-in Capital

980.0k312.4m

Retained Earnings

(1.1m)(61.1m)

Total Equity

(135.0k)251.3m

Financial Leverage

-0.1 x1 x

Quarterly

USDQ2, 2020Q3, 2020

Cash

11.2m278.6m

Prepaid Expenses

9.0k604.0k

Current Assets

11.3m279.2m

PP&E

19.0k28.0k

Total Assets

11.3m279.3m

Accounts Payable

1.3m8.8m

Current Liabilities

20.1m11.6m

Total Liabilities

20.1m11.6m

Preferred Stock

18.0m

Additional Paid-in Capital

980.0k310.5m

Retained Earnings

(27.8m)(42.8m)

Total Equity

(26.8m)267.6m

Financial Leverage

-0.4 x1 x

Taysha Gene Therapies Cash Flow

Annual

USDFY, 2019FY, 2020

Net Income

(1.1m)(60.0m)

Depreciation and Amortization

9.0k

Accounts Payable

(6.6m)

Cash From Operating Activities

(30.7m)

Purchases of PP&E

(82.0k)

Cash From Investing Activities

(9.1m)

Cash From Financing Activities

291.1m

Net Change in Cash

251.3m

Interest Paid

28.0k

Quarterly

USDQ2, 2020Q3, 2020

Net Income

(26.7m)(41.7m)

Depreciation and Amortization

3.0k

Accounts Payable

1.2m5.4m

Cash From Operating Activities

(4.2m)(10.9m)

Purchases of PP&E

(31.0k)

Cash From Investing Activities

(3.0m)(3.0m)

Cash From Financing Activities

18.4m292.5m

Net Change in Cash

11.2m278.6m

Interest Paid

27.0k28.0k

Taysha Gene Therapies Ratios

USDFY, 2019

Financial Leverage

-0.1 x